[3-(1,1-二甲基乙基)苯氧基]乙酸 | 1878-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [3-(1,1-二甲基乙基)苯氧基]乙酸
• 英文名称: 2-(3-tert-butylphenoxy)acetic acid
• 英文别名: (3-tert-butyl-phenoxy)-acetic acid；(3-tert-Butyl-phenoxy)-essigsaeure；[3-(1,1-dimethylethyl)phenoxy]acetic acid
• CAS: 1878-55-3
• 化学式: C₁₂H₁₆O₃
• mdl: MFCD02727892
• 分子量: 208.257
• InChiKey: TZCJVGQCSABBGD-UHFFFAOYSA-N

物化性质

• 熔点：
  116.5 °C
• 沸点：
  320.3±25.0 °C(Predicted)
• 密度：
  1.088±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  [3-(1,1-二甲基乙基)苯氧基]乙酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-(3-Tert-butylphenoxy)acetyl chloride
  参考文献：
  名称：

  Design, synthesis and structure–activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

  摘要：

  The free fatty acid receptor 1 (FFA1) has attracted extensive attention as a novel antidiabetic target in the last decade. Several FFA1 agonists reported in the literature have been suffered from relatively high molecular weight and lipophilicity. We have previously reported the FFA1 agonist 1. Based on the common amide structural characteristic of SAR1 and NIH screened compound, we here describe the continued structure-activity exploration to decrease the molecular weight and lipophilicity of the compound 1 series by converting various amide linkers. All of these efforts lead to the discovery of the preferable lead compound 18, a compound with considerable agonistic activity, high LE and LLE values, lower lipophilicity than previously reported agonists, and appreciable efficacy on glucose tolerance in both normal and type 2 diabetic mice. (c) 2015 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2015.09.010
• 作为产物：
  描述：

  3-叔丁基苯酚 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 [3-(1,1-二甲基乙基)苯氧基]乙酸
  参考文献：
  名称：

  潜在的瞬时受体潜在香草酸1拮抗剂的发现：苯氧基乙酰胺衍生物的设计与合成

  摘要：

  我们旨在发现一种新型的瞬时受体电位类香草素1（TRPV1）拮抗剂，因为此类拮抗剂可能是治疗各种疾病的候选药物。我们修改了命中化合物7（人TRPV1 IC 50  = 411 nM）的结构，并将其吡咯烷基基团转变为（羟乙基）甲基氨基，从而大大提高了抑制活性（15d；人TRPV1 IC 50  = 33 nM）。另外，15d改善了大鼠体内的膀胱过度活动。

  DOI：

  10.1016/j.bmcl.2013.04.016

文献信息

• Radical Decarboxylative Fluorination of Aryloxyacetic Acids Using<i>N</i>-Fluorobenzenesulfonimide and a Photosensitizer
  作者：Joe C. T. Leung、Glenn M. Sammis

  DOI：10.1002/ejoc.201500038

  日期：2015.4

  carboxylic acids was developed that uses photosensitizers and N-fluorobenzenesulfonimide (NFSI). Utilization of the oxidatively mild fluorine transfer agent NFSI enabled the synthesis of fluoromethyl ethers that were previously inaccessible with decarboxylative fluorinations performed with Selectfluor. Mechanistic studies are consistent with the photosensitizer effecting oxidation of the aryloxyacetic acid

  氟化甲氧基芳烃正在成为农用化学品和药物中的重要基序。开发了一种通过羧酸的直接氟脱羧合成单氟甲氧基芳烃的新技术，该技术使用光敏剂和 N-氟苯磺酰亚胺 (NFSI)。利用氧化性温和的氟转移剂 NFSI 能够合成氟甲基醚，而以前使用 Selectfluor 进行脱羧氟化是无法获得这些氟甲基醚的。机理研究与影响芳氧基乙酸氧化的光敏剂一致。
• [EN] MACROCYCLIC COMPOUNDS AND THEIR USE AS CDK8 INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CDK8
  申请人：CT NAC INVESTIGACIONES ONCOLOGICAS CNIO

  公开号：WO2013001310A1

  公开（公告）日：2013-01-03

  There is provided compounds of formula I, wherein R1, R2, R3, R4, X, Y, Z and ring A have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了具有式I的化合物，其中R1、R2、R3、R4、X、Y、Z和环A的含义如描述中所给，并且其药学上可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白质或脂质激酶（例如CDK8）的疾病中非常有用，特别是在癌症或增生性疾病的治疗中。
• Discovery of potent transient receptor potential vanilloid 1 antagonists: Design and synthesis of phenoxyacetamide derivatives
  作者：Eiki Takahashi、Noriyuki Hirano、Takashi Nagahara、Satoru Yoshikawa、Shinobu Momen、Hiroshi Yokokawa、Ryoji Hayashi

  DOI：10.1016/j.bmcl.2013.04.016

  日期：2013.6

  We aimed to discover a novel type of transient receptor potential vanilloid 1 (TRPV1) antagonist because such antagonists are possible drug candidates for treating various disorders. We modified the structure of hit compound 7 (human TRPV1 IC50 = 411 nM) and converted its pyrrolidino group to a (hydroxyethyl)methylamino group, which substantially improved inhibitory activity (15d; human TRPV1 IC50 = 33 nM)

  我们旨在发现一种新型的瞬时受体电位类香草素1（TRPV1）拮抗剂，因为此类拮抗剂可能是治疗各种疾病的候选药物。我们修改了命中化合物7（人TRPV1 IC 50  = 411 nM）的结构，并将其吡咯烷基基团转变为（羟乙基）甲基氨基，从而大大提高了抑制活性（15d；人TRPV1 IC 50  = 33 nM）。另外，15d改善了大鼠体内的膀胱过度活动。
• INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：Roth Juergen Gerald

  公开号：US20070004757A1

  公开（公告）日：2007-01-04

  The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R 1 to R 6 and X are as defined in Claim 1 , to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.

  本发明涉及6-位取代的吲哚酮衍生物，其化学式为其中R1至R6和X如权利要求1所定义，以及它们的互变异构体、对映异构体、非对映异构体、混合物和盐，特别是其生理上可接受的盐，具有有用的药理学性质，特别是在抑制各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞的增殖方面，以及包含这些化合物的药物、它们的用途和制备方法。
• Novel kinase inhibitors
  申请人：Thormann Michael

  公开号：US20120329780A1

  公开（公告）日：2012-12-27

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种公式（I）的新型化合物，该化合物能够抑制一个或多个激酶，尤其是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。该化合物在治疗多种疾病方面有应用，这些疾病包括自身免疫性疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼病、传染病和激素相关疾病。